Payment overview · 2025
General Payments
$255.82
3 reported records · 2 companies
Healthcare provider profile · identity verified
Shawn M Hamm, DO
Allopathic & Osteopathic Physicians|Family Medicine · CONNELLY SPRINGS, NC · NPI 1245725480
Verified facts
What the public records show
CMS Open Payments records show Shawn M Hamm, DO received $255.82 in general payments during 2025 across 3 reported records.
Exact Sciences Corporation accounted for 80.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 3 associated products.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $205.94 | 80.5% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $49.88 | 19.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $255.82 | 3 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $105.77 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $100.17 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $49.88 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
54 | 12 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 277 | 96 |
| Levothyroxine Sodium | Levothyroxine Sodium | 261 | 60 |
| Omeprazole | Omeprazole | 231 | 66 |
| Gabapentin | Gabapentin | 192 | 41 |
| Lisinopril | Lisinopril | 171 | 62 |
| Losartan Potassium | Losartan Potassium | 170 | 47 |
| Amlodipine Besylate | Amlodipine Besylate | 156 | 52 |
| Tamsulosin Hcl | Tamsulosin Hcl | 118 | 35 |
| Escitalopram Oxalate | Escitalopram Oxalate | 111 | 35 |
| Zolpidem Tartrate | Zolpidem Tartrate | 111 | 18 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 106 | 42 |
| Metformin Hcl | Metformin Hcl | 103 | 38 |
| Furosemide | Furosemide | 100 | 41 |
| Pantoprazole Sodium | Pantoprazole Sodium | 99 | 36 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 96 | 44 |
| Meloxicam | Meloxicam | 96 | 37 |
| Clonazepam | Clonazepam | 90 | 18 |
| Trazodone Hcl | Trazodone Hcl | 89 | 30 |
| Simvastatin | Simvastatin | 88 | 29 |
| Celecoxib | Celecoxib | 87 | 21 |
| Lorazepam | Lorazepam | 83 | 15 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 79 | 30 |
| Tramadol Hcl | Tramadol Hcl | 79 | 22 |
| Metoprolol Succinate | Metoprolol Succinate | 78 | 34 |
| Jardiance | Empagliflozin | 75 | 23 |
| Eliquis | Apixaban | 72 | 21 |
| Allopurinol | Allopurinol | 71 | 24 |
| Duloxetine Hcl | Duloxetine Hcl | 70 | 26 |
| Metformin Hcl Er | Metformin Hcl | 70 | 19 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 68 | 17 |
| Sertraline Hcl | Sertraline Hcl | 68 | 19 |
| Montelukast Sodium | Montelukast Sodium | 63 | 21 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 63 | 21 |
| Fluticasone Propionate | Fluticasone Propionate | 62 | 22 |
| Hydrochlorothiazide | Hydrochlorothiazide | 60 | 18 |
| Pravastatin Sodium | Pravastatin Sodium | 58 | 18 |
| Diazepam | Diazepam | 57 | 13 |
| Famotidine | Famotidine | 54 | 17 |
| Ozempic | Semaglutide | 54 | 12 |
| Quetiapine Fumarate | Quetiapine Fumarate | 53 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 51 | 19 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 49 | 14 |
| Pregabalin | Pregabalin | 49 | 13 |
| Tizanidine Hcl | Tizanidine Hcl | 48 | 25 |
| Prednisone | Prednisone | 46 | 35 |
| Ropinirole Hcl | Ropinirole Hcl | 44 | 13 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 42 | 11 |
| Citalopram Hbr | Citalopram Hydrobromide | 41 | 12 |
| Alprazolam | Alprazolam | 40 | 13 |
| Clopidogrel | Clopidogrel Bisulfate | 40 | 14 |
| Fluoxetine Hcl | Fluoxetine Hcl | 40 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 39 | suppressed |
| Carvedilol | Carvedilol | 38 | 15 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 38 | suppressed |
| Spironolactone | Spironolactone | 37 | 15 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 37 | 17 |
| Alendronate Sodium | Alendronate Sodium | 34 | suppressed |
| Synthroid | Levothyroxine Sodium | 33 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 32 | 11 |
| Buspirone Hcl | Buspirone Hcl | 31 | 11 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 30 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 28 | 14 |
| Glipizide Er | Glipizide | 27 | suppressed |
| Glimepiride | Glimepiride | 26 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 26 | suppressed |
| Baclofen | Baclofen | 25 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 25 | suppressed |
| Atenolol | Atenolol | 24 | suppressed |
| Estradiol | Estradiol | 23 | suppressed |
| Nystatin | Nystatin | 23 | 12 |
| Valacyclovir | Valacyclovir Hcl | 23 | suppressed |
| Azithromycin | Azithromycin | 22 | 21 |
| Methocarbamol | Methocarbamol | 22 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 22 | suppressed |
| Topiramate | Topiramate | 22 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 22 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 21 | suppressed |
| Potassium Chloride | Potassium Chloride | 21 | suppressed |
| Bupropion Xl | Bupropion Hcl | 20 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 20 | 17 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 20 | 16 |
| Finasteride | Finasteride | 19 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 19 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 18 | 14 |
| Cephalexin | Cephalexin | 18 | 14 |
| Fluconazole | Fluconazole | 18 | 15 |
| Pioglitazone Hcl | Pioglitazone Hcl | 18 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 18 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 17 | suppressed |
| Lovastatin | Lovastatin | 17 | suppressed |
| Mounjaro | Tirzepatide | 17 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 17 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Valsartan | Valsartan | 17 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 16 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 16 | suppressed |
| Ondansetron Odt | Ondansetron | 16 | suppressed |
| Trulicity | Dulaglutide | 16 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 15 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 15 | suppressed |
| Ezetimibe | Ezetimibe | 15 | suppressed |
| Lamotrigine | Lamotrigine | 15 | suppressed |
| Xarelto | Rivaroxaban | 15 | suppressed |
| Amantadine | Amantadine Hcl | 14 | suppressed |
| Chlorthalidone | Chlorthalidone | 14 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 14 | suppressed |
| Entresto | Sacubitril/Valsartan | 14 | suppressed |
| Eszopiclone | Eszopiclone | 14 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 14 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 13 | suppressed |
| Myrbetriq | Mirabegron | 13 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 13 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 13 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 13 | suppressed |
| Cefdinir | Cefdinir | 12 | 11 |
| Clobetasol Propionate | Clobetasol Propionate | 12 | suppressed |
| Glipizide | Glipizide | 12 | suppressed |
| Ketoconazole | Ketoconazole | 12 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 11 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 11 | suppressed |
| Linzess | Linaclotide | 11 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $255.82 · 3 records | Exact Sciences Corporation | Cologuard Collection Kit, The Cologuard Plus Collection Kit, Wegovy | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with Novo Nordisk Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error